Print Page Print Page  |  RSS Feeds RSS Feeds  |  E-mail Alerts E-mail Alerts  |  IR Contacts IR Contacts  |  Financial Tear Sheet Financial Tear Sheet

This Site contains information and press releases about us. This information should be considered accurate only as of the date prepared. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Delcath Systems, Inc. is not obligated to update the press releases and information contained in this section of the Site.
Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
02/11/19Delcath Announces Health Authority Approval for CHEMOSAT in Brazil
Discussions Underway With Potential Commercialization Partners NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company has received medical device approval for the CHEMOSAT® Hepatic Delivery System (CHEMOSAT) from the national health authority in Brazil. The approval of CHEMOSAT as a Class 3 medical device was issued by the Agência Nac... 
Printer Friendly Version
02/08/19Delcath Announces Acceptance of Abstract for Oral Presentation at ECIO 2019
NEW YORK, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces an abstract from a prospective phase 2 study conducted in the Netherlands of the use of the Delcath Hepatic CHEMOSAT® Delivery System to treat patients with metastatic ocular melanoma with liver metastases, has been accepted for oral presentation and as a poster at the European Conference on Interv... 
Printer Friendly Version